ArticleEuropean journal of haematology2019

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Florian Huemer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.